ARTICLE | Clinical News
GL701-DHEA: Began Phase II/III trial
May 16, 1994 7:00 AM UTC
Genelabs Technologies Inc. (GNLB), Redwood City, Calif. Product: GL701-DHEA dehydro- epiandrosterone Indication: Mild to moderate lupus erythematosus Status: Began Phase II/III trial in 200 women who ...